Close Menu

NEW YORK – A team led by researchers at the Massachusetts Institute of Technology has developed a method that measures dysregulated protease activity for the early detection of lung cancer.

Detailed in a paper published last week in Science Translational Medicine, the test is one of several protease-based diagnostics developed by the MIT team, which in 2015 spun out a company, Glympse Bio, to commercialize the technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Nov
03
Sponsored by
Agilent

Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
09
Sponsored by
Akoya Biosciences

Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context. 

Dec
01
Sponsored by
Roche

Management of viral infections is critical to prevent severe morbidities and consequences in immune-suppressed transplant patients.